Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label maintenance certolizumab pegol study in Crohn's disease responders from study C87037
2014-004354-34Phase 2
- Sponsor
- UCB
- Start
- Feb 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoint: Percentage of Crohn's Disease Activity Index responders at Week 26.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-004354-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004354-34.